ReviewLipids in health and disease2024
Updated mechanisms of MASLD pathogenesis.
Review in Lipids in health and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 195 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
195 citing papers in PubMed, 1 synthesis or guideline pooled it, 186 citations in OpenAlex.
- MASLD and sarcopenia research (2012-2025): a multi-database bibliometric analysis.Frontiers in nutrition · 2026Pooled it
- Effect of Tomato Consumption on Liver Steatosis in MASLD: A Randomized Controlled Trial (POMOSANO Study).Nutrients · 2026Trial
- Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.International journal of molecular sciences · 2025Trial
- Betaine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms of Action and Therapeutic Potential.Antioxidants (Basel, Switzerland) · 2026Review
- From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD.International journal of molecular sciences · 2026Review
- Ketogenesis as a Metabolic Checkpoint in MASLD: Implications for Disease Progression and Therapy.Metabolites · 2026Review
- Lipid Metabolic Reprogramming and Bioactive Lipid Signaling in MASLD: Molecular Mechanisms, Pathogenesis and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Liposomal Nanocarriers in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Formulation Design, Targeting Strategies, and Therapeutic Outcomes.Current issues in molecular biology · 2026Review
- Inulin alleviates metabolic dysfunction-associated steatotic liver disease-induced bone loss potentially by activating the Nrf2/GPX4 signaling pathway.Molecular and cellular biochemistry · 2026Article
- Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum.Biomedicines · 2026Review
- Integrating Network Pharmacology and Metabolomics to Decipher the Mechanisms Underlying the Therapeutic Effects of Wuzhi Dripping Pills Against MASLD.Metabolites · 2026Article
- Triglyceride-to-HDL Cholesterol Ratio is Associated with Hepatic Steatosis but not Fibrosis in Patients with Severe Obesity: A Cross-Sectional Study.Obesity surgery · 2026Article
- Determinants of Metabolic Dysfunction-Associated Steatotic Liver Diseases in Patients with Type 2 Diabetes Mellitus.Journal of clinical medicine · 2026Article
- Lentinan Improves Sodium Arsenite-Induced Hepatic Lipid Accumulation and Ferroptosis: Role of AMPK Signaling Pathway.Toxics · 2026Article
- Metabolic dysfunction associated steatotic liver disease, cardiometabolic multimorbidity and mortality: evidence from the UK biobank.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Extracellular Vesicle-Based miRNA Profiling in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Secondary Analysis of the MULTISITE Clinical Trial.Journal of extracellular biology · 2026Article
- Deciphering cytochrome P450 reductase role in MASLD: molecular mechanisms and pathophysiological implications.Nature reviews. Gastroenterology & hepatology · 2026Review
- GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials.Hepatology international · 2026Article
- Dapagliflozin attenuates hepatic steatosis and induces a fasting-mimicking metabolic state in C57BL/6 mice.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Liver-Derived Peptides from Livestock Processing By-Products: Insights into Generation, Bioactivity, and Taste Properties.Foods (Basel, Switzerland) · 2026Review
135 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) has garnered considerable attention globally. Changing lifestyles, over-nutrition, and physical inactivity have promoted its development. MASLD is typically accompanied by obesity and is strongly linked to metabolic syndromes. Given that MASLD prevalence is on the rise, there is an urgent need to elucidate its pathogenesis. Hepatic lipid accumulation generally triggers lipotoxicity and induces MASLD or progress to metabolic dysfunction-associated steatohepatitis (MASH) by mediating endoplasmic reticulum stress, oxidative stress, organelle dysfunction, and ferroptosis. Recently, significant attention has been directed towards exploring the role of gut microbial dysbiosis in the development of MASLD, offering a novel therapeutic target for MASLD. Considering that there are no recognized pharmacological therapies due to the diversity of mechanisms involved in MASLD and the difficulty associated with undertaking clinical trials, potential targets in MASLD remain elusive. Thus, this article aimed to summarize and evaluate the prominent roles of lipotoxicity, ferroptosis, and gut microbes in the development of MASLD and the mechanisms underlying their effects. Furthermore, existing advances and challenges in the treatment of MASLD were outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.